Literature DB >> 14607208

Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or idiopathic dilated cardiomyopathy.

F Waagstein1, O Strömblad, B Andersson, M Böhm, M Darius, W Delius, F Goss, K J Osterziel, M Sigmund, S-P Trenkwalder, I Wahlqvist.   

Abstract

BACKGROUND: the effects of long-term administration of beta-blockers on left ventricular (LV) function during exercise in patients with ischemic heart disease (IHD) and idiopathic dilated cardiomyopathy (DCM) are controversial. PATIENTS AND METHODS: patients with stable congestive heart failure (CHF) (New York heart association [NYHA] class II and III) and ejection fraction (EF) < or =0.40 were randomized to metoprolol, 50 mg t.i.d. or placebo for 6 months. Patients were divided into two groups: ischemic heart disease (IHD) and idiopathic dilated cardiomyopathy (DCM). The mean EF was 0.29 in both groups and 92% were taking angiotensin-converting enzyme (ACE) inhibitors. In the IHD group, 84% had suffered a myocardial infarction (MI) and 64% had undergone revascularization at least 6 months before the study. LV volumes were measured by equilibrium radionuclide angiography. Mitral regurgitation was assessed by Doppler echocardiography. All values are changes for metoprolol subtracted by changes for placebo.
RESULTS: metoprolol improved LV function markedly both at rest and during sub-maximal exercise in both groups. The mean increase in EF was 0.069 at rest (P<0.001) and 0.078 during submaximal exercise (P<0.001). LV end-diastolic volume decreased by 22 ml at rest (P=0.006) and by 15 ml during exercise (P=0.006). LV end-systolic volume decreased by 23 ml both at rest (P=0.001) and during exercise (P=0.004). Exercise time increased by 39 s (P=0.08). In the metoprolol group, mitral regurgitation decreased (P=0.0026) and only one patient developed atrial fibrillation vs. eight in the placebo group (P=0.01).
CONCLUSION: metoprolol improves EF both at rest and during submaximal exercise and prevents LV dilatation in mild to moderate CHF due to IHD or DCM.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14607208     DOI: 10.1016/s1388-9842(03)00105-3

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  18 in total

1.  Clinical impact of echocardiography parameters and molecular biomarkers in heart failure: Correlation of ACE2 and MCP-1 polymorphisms with echocardiography parameters: A comparative study.

Authors:  Mălina Suciu-Petrescu; Anamaria Truta; Mihai Domnutiu Suciu; Adrian Pavel Trifa; Denisa Petrescu; Horia Ștefan Roșianu; Octavia Sabin; Daciana Elena Popa; Antonia Eugenia Macarie; Ștefan Cristian Vesa; Anca Dana Buzoianu
Journal:  Exp Ther Med       Date:  2021-04-28       Impact factor: 2.447

Review 2.  Left ventricular ejection fraction as therapeutic target: is it the ideal marker?

Authors:  V Katsi; G Georgiopoulos; A Laina; E Koutli; J Parissis; C Tsioufis; P Nihoyannopoulos; D Tousoulis
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

3.  The effect of metoprolol succinate on the cardiac function of patients with thalassaemia cardiomyopathy: a double-blind randomised study.

Authors:  Javad Kojury; Abdolali Zolghadrasli; Mehran Karimi; Mohammad Ali Babaee Beighi; Soha Namazi
Journal:  Heart Asia       Date:  2014-04-17

Review 4.  Atrial Remodeling And Atrial Fibrillation: Mechanistic Interactions And Clinical Implications.

Authors:  Bandar Al Ghamdi; Walid Hassan
Journal:  J Atr Fibrillation       Date:  2009-06-01

5.  Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction.

Authors:  Sergio Manzano-Fernández; Thomas Mueller; Domingo Pascual-Figal; Quynh A Truong; James Louis Januzzi
Journal:  Am J Cardiol       Date:  2011-01-15       Impact factor: 2.778

6.  Biventricular pacing: impact on exercise-induced increases in mitral insufficiency in patients with chronic heart failure.

Authors:  Klaus K Witte; Zion Sasson; Joan A Persaud; Robynn Jolliffe; Robert W Wald; John D Parker
Journal:  Can J Cardiol       Date:  2008-05       Impact factor: 5.223

Review 7.  Heart rate reduction in coronary artery disease and heart failure.

Authors:  Roberto Ferrari; Kim Fox
Journal:  Nat Rev Cardiol       Date:  2016-05-26       Impact factor: 32.419

8.  Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Authors:  Nicole Martin; Karthick Manoharan; Ceri Davies; R Thomas Lumbers
Journal:  Cochrane Database Syst Rev       Date:  2021-05-22

Review 9.  Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Authors:  Nicole Martin; Karthick Manoharan; James Thomas; Ceri Davies; R Thomas Lumbers
Journal:  Cochrane Database Syst Rev       Date:  2018-06-28

Review 10.  Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis.

Authors:  Saurav Chatterjee; Giuseppe Biondi-Zoccai; Antonio Abbate; Fabrizio D'Ascenzo; Davide Castagno; Benjamin Van Tassell; Debabrata Mukherjee; Edgar Lichstein
Journal:  BMJ       Date:  2013-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.